CNS Drugs

, Volume 32, Issue 3, pp 189–196 | Cite as

Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis

  • Simona Lattanzi
  • Francesco Brigo
  • Elisabetta Grillo
  • Claudia Cagnetti
  • Alberto Verrotti
  • Gaetano Zaccara
  • Mauro Silvestrini
Systematic Review



In the treatment of pediatric epilepsy, there is a critical demand for effective and safe therapeutic options to address patients’ unmet clinical needs. Eslicarbazepine acetate is a novel once-daily antiepileptic drug and a third-generation single enantiomer member of the dibenzazepine family.


The objective of this study was to evaluate the efficacy and safety of eslicarbazepine acetate as add-on treatment for focal-onset seizures in pediatric patients using meta-analytical techniques.


Randomized, placebo-controlled, single- or double-blinded add-on trials of eslicarbazepine acetate in patients < 18 years of age with focal-onset seizures uncontrolled by concomitant stable antiepileptic drug regimens were identified through a systematic literature search. The assessed outcomes included the mean relative change and ≥ 50% reduction in the baseline seizure frequency, the incidence of treatment withdrawal, serious adverse events, and treatment-emergent adverse events. Risk ratio and weighted mean difference with 95% confidence intervals were estimated for dichotomous/continuous outcomes.


Two trials were included involving 386 participants (age range 2–18 years), 217 for eslicarbazepine acetate and 169 for placebo groups, respectively. At the dosage of 30 mg/kg/day, eslicarbazepine acetate-treated patients had a significantly greater reduction in baseline seizure frequency (weighted mean difference − 21.67, 95% confidence interval − 40.87 to − 2.46; p = 0.027) and 58 patients (44.6%) were seizure responders compared with 27 controls (29.7%) [risk ratio 1.48, 95% confidence interval 0.99–2.20; p = 0.055]. There were no differences in treatment withdrawal (risk ratio 1.24, 95% confidence interval 0.65–2.37; p = 0.513), serious adverse events (risk ratio 1.40, 95% confidence interval 0.69–2.86; p = 0.350), and treatment-emergent adverse events (risk ratio 1.07, 95% confidence interval 0.94–1.22; p = 0.313).


Adjunctive eslicarbazepine acetate could be an effective well-tolerated option in children and adolescents with focal-onset seizures uncontrolled by one or more concomitant anti-epileptic drugs.


Compliance with Ethical Standards


No funding has been received for the conduct of this study.

Conflict of interest

Simona Lattanzi, Claudia Cagnetti, Alberto Verrotti, and Mauro Silvestrini have no conflicts of interest directly relevant to the content of this study. Francesco Brigo acted as a consultant for Eisai. Elisabetta Grillo is an employee of Eisai s.r.l. Gaetano Zaccara has received speaker’s or consultancy fees from Eisai, Sanofi-Aventis, and UCB Pharma.

Supplementary material

40263_2018_504_MOESM1_ESM.pdf (447 kb)
Supplementary material 1 (PDF 447 kb)


  1. 1.
    Oka E, Ohtsuka Y, Yoshinaga H, Murakami N, Kobayashi K, Ogino T. Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan. Epilepsia. 2006;47:626–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Cagnetti C, Lattanzi S, Foschi N, Provinciali L, Silvestrini M. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014;83:339–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Guerrini R. Epilepsy in children. Lancet. 2006;367:499–524.CrossRefPubMedGoogle Scholar
  4. 4.
    Forsgren L. Incidence and prevalence. In: Wallace SJ, Farrell K, editors. Epilepsy in children. 2nd ed. London: Arnold; 2004. p. 21–5.CrossRefGoogle Scholar
  5. 5.
    Tsuboi T. Prevalence and incidence of epilepsy in Tokyo. Epilepsia. 1988;29:103–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34:453–68.CrossRefPubMedGoogle Scholar
  7. 7.
    Rosati A, De Masi S, Guerrini R. Antiepileptic drug treatment in children with epilepsy. CNS Drugs. 2015;29:847–63.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wirrell EC. Predicting pharmacoresistance in pediatric epilepsy. Epilepsia. 2013;54(Suppl. 2):19–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Dwivedi R, Ramanujam B, Chandra PS, Sapra S, Gulati S, Kalaivani M, Garg A, Bal CS, Tripathi M, Dwivedi SN, Sagar R, Sarkar C, Tripathi M. Surgery for drug-resistant epilepsy in children. N Engl J Med. 2017;377:1639–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Donner EJ, Camfield P, Brooks L, Buchhalter J, Camfield C, Loddenkemper T, Wirrell E. Understanding death in children with epilepsy. Pediatr Neurol. 2017;70:7–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Lattanzi S, Cagnetti C, Foschi N, Lorusso A, Provinciali L, Silvestrini M. Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy. Acta Neurol Scand. 2018;137(1):29–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Doty P, Hebert D, Mathy FX, Byrnes W, Zackheim J, Simontacchi K. Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci. 2013;1291:56–68.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide during pregnancy and breastfeeding. Neurol Neurochir Pol. 2017;51:266–9.PubMedGoogle Scholar
  15. 15.
    Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Higgins JPT, Green S, editors. The Cochrane Collaboration, 2011. Available from: Accessed Oct 2017.
  17. 17.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMedGoogle Scholar
  19. 19.
    Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86:1344–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson’s disease: a systematic review with meta-analysis. J Neurol. 2017. (epub ahead of print).
  21. 21.
    Lattanzi S, Cagnetti C, Provinciali L, Silvestrini M. How should we lower blood pressure after cerebral hemorrhage? A systematic review and meta-analysis. Cerebrovasc Dis. 2017;43:207–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Lattanzi S, Cagnetti C, Danni M, Provinciali L, Silvestrini M. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol. 2017;264:1697–704.CrossRefPubMedGoogle Scholar
  23. 23. Eslicarbazepine acetate as therapy for refractory partial seizures in children. Available from: Accessed 28 Feb 2018.
  24. 24. Effects of eslicarbazepine acetate on cognitive function in children with partial onset seizures. Available from: Accessed 28 Feb 2018.
  25. 25.
    European Medicines Agency. Assessment report: Zebinix. International non-proprietary name: eslicarbazepine acetate. Available from: Accessed 28 Feb 2018.
  26. 26.
    Almeida L, Minciu I, Nunes T, Butoianu N, Falcão A, Magureanu SA, Soares-da-Silva P. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol. 2008;48:966–77.CrossRefPubMedGoogle Scholar
  27. 27.
    Sarco DP, Bourgeois BF. The safety and tolerability of newer antiepileptic drugs in children and adolescents. CNS Drugs. 2010;24:399–430.CrossRefPubMedGoogle Scholar
  28. 28.
    Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs: a meta-analysis of placebo-controlled studies. Seizure. 2008;17:405–21.CrossRefPubMedGoogle Scholar
  29. 29.
    Elger C, Koepp M, Trinka E, Villanueva V, Chaves J, Ben-Menachen E, Kowacs PA, Gil-Nagel A, Moreira J, Gama H, Rocha JF, Soares-da-Silva P. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: data from four double-blind placebo-controlled pivotal phase III clinical studies. CNS Neurosci Ther. 2017;23:961–72.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Gama H, Vieira M, Costa R, Graça J, Magalhães LM, Soares-da-Silva P. Safety profile of eslicarbazepine acetate as add-on therapy in adults with refractory focal-onset seizures: from clinical studies to 6 years of post-marketing experience. Drug Saf. 2017;40:1231–40.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gaitatzis A, Sander JW. The long-term safety of antiepileptic drugs. CNS Drugs. 2013;27:435–55.CrossRefPubMedGoogle Scholar
  32. 32.
    Guerrini R, Zaccara G, la Marca G, Rosati A. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf. 2012;35:519–33.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Simona Lattanzi
    • 1
  • Francesco Brigo
    • 2
    • 3
  • Elisabetta Grillo
    • 4
  • Claudia Cagnetti
    • 1
  • Alberto Verrotti
    • 5
  • Gaetano Zaccara
    • 6
  • Mauro Silvestrini
    • 1
  1. 1.Neurological Clinic, Department of Experimental and Clinical MedicineMarche Polytechnic UniversityAnconaItaly
  2. 2.Department of Neuroscience, Biomedicine and Movement ScienceUniversity of VeronaVeronaItaly
  3. 3.Division of Neurology“Franz Tappeiner” HospitalMeranoItaly
  4. 4.Medical Department Eisai s.r.l.San Donato MilaneseItaly
  5. 5.Department of PediatricsUniversity of L’AquilaL’AquilaItaly
  6. 6.Unit of Neurology, Department of MedicineUSL Centro Toscana Health AuthorityFirenzeItaly

Personalised recommendations